Description

RT GLP3 10 mg

RETA GLP3

Overview
RT GLP3 10 mg is provided as a lyophilized research peptide analogue for Research Use Only (RUO). Each vial is specified to ≥99% HPLC purity with LC–MS-verified identity, supporting traceability and reproducibility in GPCR pharmacology, metabolic signaling, and receptor-selectivity studies.

Clinical Data:

GLP-3RT: Triple–Hormone-Receptor Agonist for Obesity — A Phase 2 Trial

GLP-3RT: A Study (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)

GLP-3RT: Triple-Hormone-Receptor Agonist Study for Obesity – A Phase 2 Trial

Key specifications

• Intended use: RUO — not for human or veterinary use

• Purity: ≥99% (HPLC)

• Identity: LC–MS verified

• Form: Lyophilized powder, sealed vial

• Content: 10 mg RT analogue

• Storage protect from light/moisture

• Handling: Allow vial to reach room temperature before opening; minimize humidity exposure; re-seal promptly

Compliance
Research Use Only (RUO). Not for human or veterinary use. No dosing, administration, compounding, or medical guidance is provided or implied.

Research Domains & Endpoints (RUO)

Incretin & glucagon receptor pharmacology

• Endpoints: receptor activation at GIPR, GLP-1R, GCGR; cAMP accumulation; β-arrestin recruitment; receptor internalization/desensitization

• Assays: GPCR reporter lines (CRE-luc, cAMP HTRF), BRET β-arrestin assays, ERK/MAPK time-courses, competitive binding

Metabolic signaling & glucose homeostasis

• Endpoints: AKT/AMPK phosphorylation, insulin-signaling readouts, glycogen synthesis enzymes, GLUT translocation

• Assays: hepatocyte/adipocyte/myotube models; Western/qPCR for p-AKT, p-AMPK, GSK-3β; glucose uptake & glycogen assays

Hepatic metabolism & lipid handling

• Endpoints: gluconeogenesis markers (PEPCK, G6Pase), SREBP-1c, ACC/FAS (lipogenesis), β-oxidation markers (CPT1)

• Assays: primary hepatocytes or hepatic cell lines; tracer studies; targeted metabolomics; Seahorse OCR/ECAR for substrate switching

Energy expenditure & adipose biology

• Endpoints: browning markers (UCP1, PRDM16, PGC-1α), lipolysis/lipogenesis balance, mitochondrial density

• Assays: white→beige induction, Oil Red O for lipid content, glycerol/NEFA release, mitochondrial staining & respirometry

Appetite/central pathway models (methodology)

• Endpoints: hypothalamic markers (POMC/AgRP), c-Fos mapping, cAMP/PKA/CREB signaling in neuronal models

• Assays: hypothalamic neuron cultures or slices, immediate-early gene panels, phospho-protein kinetics (methodological mapping only)

Cardiometabolic & vascular readouts (preclinical)

• Endpoints: endothelial NO/eNOS pathway markers, heart-rate variability (HRV) metrics, inflammatory cytokine panels

• Assays: wire myography/endothelial assays, telemetry in animal models, ELISA/chemiluminescent arrays

PK/PD & selectivity characterization

• Endpoints: potency/efficacy at each receptor (EC50/Emax), bias factors, stability in matrices (HPLC/LC-MS)

• Assays: concentration–response curves across GIPR/GLP-1R/GCGR systems; plasma/serum stability; in-vitro DMPK panels